Legend-Backed Immunotherapy Firm Shanghai Cell Therapy Group Co. Secures $136M Series C Round

This Data Is Locked!

This area is available only to Subscribers.

Shanghai Cell Therapy Group Co., a Chinese biotech company, has completed an RMB925 million (US$135.71 million) series C round of financing, led by China Pacific... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?